Ethicon gets OK for handheld biopsy unit

Article

Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the

Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the Cincinnati-based division of Johnson & Johnson. Ethicon expects Mammotome Hand Held will be employed in physicians’ offices, breast care centers, and hospitals. Using ultrasound guidance, Mammotome Hand Held vacuums out suspicious tissue for examination, according to the company. The original table-mounted Mammotome has been available in the U.S. since 1995 and has been used for more than 375,000 breast biopsies.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.